Our study suggested that 3,4-DAP is well tolerated and determines a significant clinical and electrophysiological effect in more severely affected patients with AChR-MG patients, likely due to a different action than that exerted by AChE inhibitors. Here, ACHE is linked to myasthenia gravis.